Cargando…

Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer

BACKGROUND: Thyroid transcription factor-1 (TTF-1) expression in advanced non-squamous non-small cell lung cancer (NSCLC) has been associated with the efficacy of pemetrexed plus platinum chemotherapy. However, the relation between TTF-1 expression and efficacy of the combination of programmed cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ibusuki, Ritsu, Yoneshima, Yasuto, Hashisako, Mikiko, Matsuo, Norikazu, Harada, Taishi, Tsuchiya-Kawano, Yuko, Kishimoto, Junji, Ota, Keiichi, Shiraishi, Yoshimasa, Iwama, Eiji, Tanaka, Kentaro, Oda, Yoshinao, Okamoto, Isamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742625/ https://www.ncbi.nlm.nih.gov/pubmed/36519019 http://dx.doi.org/10.21037/tlcr-22-393

Ejemplares similares

Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non–small cell lung cancer
por: Iwama, Eiji, et al.
Publicado: (2023)

Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β
por: Hirayama, Aiko, et al.
Publicado: (2023)

Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD‐L1
por: Tsubouchi, Kazuya, et al.
Publicado: (2020)

HTLV‐1 seropositive patients with lung cancer treated with PD‐1 inhibitors
por: Yoneshima, Yasuto, et al.
Publicado: (2020)

(18)F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
por: Takada, Kazuki, et al.
Publicado: (2019)

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study
por: Takada, Kazuki, et al.
Publicado: (2022)

MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma
por: Nakanishi, Takayuki, et al.
Publicado: (2023)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
por: Cavazzoni, Andrea, et al.
Publicado: (2020)

Association of Mps one binder kinase activator 1 (MOB1) expression with poor disease‐free survival in individuals with non‐small cell lung cancer
por: Ando, Nobuhisa, et al.
Publicado: (2020)

Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer
por: Yu, Shili, et al.
Publicado: (2021)

Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy
por: Takada, K., et al.
Publicado: (2021)

Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)
por: Tsuchiya-Kawano, Yuko, et al.
Publicado: (2021)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Synthesis and Evaluation of Biphenyl-1,2,3-Triazol-Benzonitrile Derivatives as PD-1/PD-L1 Inhibitors
por: Narva, Suresh, et al.
Publicado: (2020)

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
por: Zhang, Pei, et al.
Publicado: (2017)

Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
por: Sun, Yuxin, et al.
Publicado: (2020)

Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
por: Arrieta, Oscar, et al.
Publicado: (2017)

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
por: D'Incecco, A, et al.
Publicado: (2015)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
por: Santarpia, Mariacarmela, et al.
Publicado: (2020)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

TTF-1 and immune checkpoint therapy in non-small cell lung cancer
por: Gumbleton, Matthew, et al.
Publicado: (2023)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-L1 expression in papillary renal cell carcinoma
por: Motoshima, Takanobu, et al.
Publicado: (2017)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer
por: Sánchez-Magraner, Lissete, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
por: Ji, Mei, et al.
Publicado: (2015)

Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
por: Nishioka, Naoya, et al.
Publicado: (2019)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Efficacy and Safety of PD-1/PD-L1 Inhibitors Plus Chemotherapy Versus PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer: A Network Analysis of Randomized Controlled Trials
por: Li, Xiang, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gi7f0fohrspt28ffh1o97d45nf